We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+42.24%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$431M
AUM Growth
+$40.6M
Cap. Flow
-$22.4M
Cap. Flow %
-5.2%
Top 10 Hldgs %
39.17%
Holding
104
New
21
Increased
36
Reduced
26
Closed
21

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$12.5M
2
AMGN icon
Amgen
AMGN
+$10.8M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.35M
4
DHR icon
Danaher
DHR
+$3.96M
5
FOCL
EDAP TMS S.A.
FOCL
+$3.61M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$13.2M
2
SDGR icon
Schrodinger
SDGR
+$10.4M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$9.41M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.05M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$9.02M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
2 Technology 1.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALA icon
76
KALA BIO
KALA
$17.1M
$1M 0.23%
59
-50
-46% -$976K
KRMD icon
77
KORU Medical Systems
KRMD
$152M
$921K 0.21%
261,722
-439,537
-63% -$1.9M
RAPT
78
DELISTED
RAPT Therapeutics
RAPT
$896K 0.21%
5,046
+1,899
+60% +$313K
CSLT
79
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$756K 0.18%
+500,393
New +$868K
AUPH icon
80
Aurinia Pharmaceuticals
AUPH
$2.06B
$644K 0.15%
49,581
-39,922
-45% -$579K
BFLY icon
81
Butterfly Network
BFLY
$2.52B
$510K 0.12%
+30,315
New +$600K
APEN
82
DELISTED
Apollo Endosurgery, Inc.
APEN
$413K 0.1%
+75,000
New +$371K
KPRX icon
83
Kiora Pharmaceuticals
KPRX
$11.7M
$375K 0.09%
+209
New +$456K
ABBV icon
84
AbbVie
ABBV
$440B
– –
-30,000
Closed -$3.21M
ALT icon
85
Altimmune
ALT
$570M
– –
-100,000
Closed -$1.13M
AXSM icon
86
Axsome Therapeutics
AXSM
$11.2B
– –
-30,758
Closed -$2.51M
BMRN icon
87
BioMarin Pharmaceuticals
BMRN
$13.6B
– –
-25,000
Closed -$2.19M
CSTL icon
88
Castle Biosciences
CSTL
$960M
– –
-22,831
Closed -$1.53M
EW icon
89
Edwards Lifesciences
EW
$53.6B
– –
-50,584
Closed -$4.62M
FATE icon
90
Fate Therapeutics
FATE
$317M
– –
-7,615
Closed -$692K
IMVT icon
91
Immunovant
IMVT
$8.8B
– –
-60,781
Closed -$2.81M
MRSN
92
DELISTED
Mersana Therapeutics
MRSN
– –
-4,921
Closed -$3.27M
NEPH icon
93
Nephros
NEPH
$47.4M
– –
-167,048
Closed -$1.43M
NVAX icon
94
Novavax
NVAX
$1.31B
– –
-34,498
Closed -$3.85M
SNDX icon
95
Syndax Pharmaceuticals
SNDX
$1.77B
– –
-31,386
Closed -$698K
UNH icon
96
UnitedHealth
UNH
$364B
– –
-23,993
Closed -$8.41M
VSTM icon
97
Verastem
VSTM
$629M
– –
-20,954
Closed -$536K
TECX
98
Tectonic Therapeutic
TECX
$720M
– –
-10,085
Closed -$1.69M
SDC
99
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
– –
-175,691
Closed -$2.1M
CNCE
100
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-50,290
Closed -$636K
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Parkman Healthcare Partners held 104 positions worth $431M, up 10% from $390M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Parkman Healthcare Partners withdrew a net $22.4M in Q1 2021, closing 21 positions and reducing 26 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $9.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Technology.

Against the trend, Parkman Healthcare Partners opened a new position in United Therapeutics worth $12.5M.

  • Parkman Healthcare Partners's largest Q1 2021 buy was United Therapeutics: 74,874 shares worth $12.5M.
  • Parkman Healthcare Partners added most to Alnylam Pharmaceuticals in Q1 2021, an estimated $4.35M increase.
  • Parkman Healthcare Partners's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $13.2M.
  • Parkman Healthcare Partners fully exited GW Pharmaceuticals Plc American Depositary Shares in Q1 2021, selling an estimated $9.41M.
  • Parkman Healthcare Partners's ten largest holdings make up 39% of its $431M portfolio in Q1 2021.
  • Parkman Healthcare Partners opened 21 new positions and closed 21 in Q1 2021.
  • Parkman Healthcare Partners's portfolio value rose 10% quarter-over-quarter to $431M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.